Clinical Trials Logo

Clinical Trial Summary

In population of intensive care unit (ICU), most studies compared atypical antipsychotics such as quetiapine with the traditional haloperidol in delirious patients of various forms and etiologies. The role of such agents in patients with hyperactive is not fully understood. This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity, length of stay in the intensive care unit, and mortality in critically ill patients.


Clinical Trial Description

A common complication in the intensive care unit (ICU) that has recently been identified is delirium. Defining delirium as a "sudden deterioration in attention, awareness, and cognition, which is not explained by any pre-existing neurocognitive disorder, but because of another medical condition," the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) clarified the definition of delirium. A dibenzothiazepine derivative with a novel and distinctive pharmacologic profile is quetiapine. The limbic system is overactive in delirium, which is one of its pathophysiologies. By obstructing the mesolimbic dopamine D2 receptors specifically, quetiapine may be able to regulate this hyperactivity. The objective of this study is to compare the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity, length of stay in ICU, and mortality in critically ill patients. This research will not receive any grants, funding, or financial aid (NOT FUNDED STUDY). Collaborators declare that they have no conflicts of interest. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05690698
Study type Interventional
Source Alexandria University
Contact
Status Completed
Phase Phase 3
Start date April 9, 2023
Completion date July 15, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03621228 - MindfulGarden in Treatment of Hyperactive Delirium in a Hospital Setting N/A
Recruiting NCT03215745 - Delirium Prevention in Patients From the Intensive Care Unit (DELA) N/A
Recruiting NCT04824144 - Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care Phase 1/Phase 2
Recruiting NCT04833023 - HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial Phase 3
Withdrawn NCT04513314 - Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium Phase 4
Terminated NCT02343575 - Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU Phase 4
Completed NCT03954769 - A Pilot Study of "Stanford Proxy Test for Delirium" (S-PTD)